Imagine your immune cells are like soldiers fighting a war against cancer, but they get tired and quit before the job is done. This technology installs a tiny 'smart sensor' inside these cells that detects when they are wearing out. Once the sensor trips, it automatically adjusts the cell's internal settings to recharge them, keeping them active and lethal against tumors.
T-cell therapies work well for blood cancers but fail in solid tumors because the cells become 'exhausted' and stop working. Current genetic switches are too static and cannot adjust to the changing environment of a tumor.
A platform of microRNA-based synthetic logic circuits and a cGMP-compliant automated manufacturing process for edited CAR-T cells.
If you are a therapy developer dealing with low efficacy in solid tumors — this project developed synthetic logic circuits that prevent T cell exhaustion. This allows your cells to remain functional longer, potentially increasing the success rate for patients with solid tumors.
If you are a manufacturer dealing with the need for more durable cancer treatments — this project developed a CRISPR/Cas-mediated sensor system. This technology can be integrated into TCR-T or TIL platforms to extend the durability of the treatment.
If you are a production facility dealing with complex cell engineering workflows — this project developed an automated cGMP-compliant manufacturing process. This enables point-of-care production of edited CAR-T cells at scale.
Based on available project data, specific pricing or cost-per-dose information is not provided.
Yes, the project specifically includes the development of an automated cGMP-compliant manufacturing process for point-of-care production.
Based on available project data, specific licensing terms are not mentioned, though the consortium includes 2 industry partners and 1 SME.
The technology is designed to be easily integrated into existing CAR-T, TCR-T, and tumor-infiltrating lymphocyte (TIL) platforms.
The project runs from 2022-09-01 to 2027-04-30, with the goal of advancing the best circuits towards the clinic.
The consortium is heavily research-driven with 5 research institutes and 1 university, but it maintains a 25% industry ratio with 2 industrial partners (including 1 SME). This balance suggests a strong academic foundation in synthetic biology and immunology paired with the necessary expertise in cGMP manufacturing to move the technology toward commercial viability.
Contact STIFTUNG LEIBNIZ-INSTITUT FUR IMMUNTHERAPIE in Germany
Contact us to explore licensing opportunities for synthetic T-cell sensors.
